Blinatumomab BiTE for MRD+ post-induction OR R/R B-ALL

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-BLINATUMOMAB` `DRUG-DEXAMETHASONE`

ID	`REG-BLINATUMOMAB-B-ALL`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-BLAST-GOKBUGET-2018` `SRC-NCCN-BCELL-2025`

Notes

Bispecific T-cell engager (BiTE) for MRD+ post-induction or R/R B-ALL. BLAST: complete MRD response 78%. TOWER: median OS 7.7 vs 4.0 mo R/R Ph-. Continuous IV + hospitalization cycle 1 limit accessibility. CRS + ICANS boxed warnings — tocilizumab + ICU support mandatory. STUB — pending Co-Lead sign-off.

Used By

Indication

IND-B-ALL-BLINATUMOMAB-MRD-OR-RR - IND-B-ALL-BLINATUMOMAB-MRD-OR-RR